SGMT ▲ +0.1% - Sagimet Biosciences Inc.
$SGMT - Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
09-OCT-2026 07:00 AM ET
Share this post
More filings for $SGMT
SGMT ▼ -1.0% - Sagimet Biosciences Inc.Oct 22, 2026SGMT - Sagimet Biosciences Inc. - SEC Filing Update (07-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 7, 2026SGMT ▼ -6.6% - Sagimet Biosciences Inc.Oct 1, 2026SGMT ▲ +14.1% - Sagimet Biosciences Inc.Sep 30, 2026SGMT ▲ +0.7% - Sagimet Biosciences Inc.Sep 30, 2026SGMT ▲ +1.1% - Sagimet Biosciences Inc.Sep 2, 2026
View full $SGMT filing history →💬 Comments
Loading comments…
Leave a comment